Media release: Hirslanden is on track
25.05.2022 | PDF | 365.54 KB
The Hirslanden Group concluded the 2021/22 financial year with success. The consistent focus on the “Continuum of Care” for each care region has also proven very effective over the course of the last financial year.
In the past financial year, Hirslanden has once again proven to be a reliable, top-quality and system-relevant partner in its handling of the pandemic. Since the start of the pandemic, the Hirslanden hospitals have treated around 2,500 patients with Covid-19 on a regional basis, around a quarter of them in intensive care. The Hirslanden hospitals have also cooperated closely with public institutions and hospitals. Overall, the Hirslanden Group looked after around 110,000 inpatients over the last business year. In addition, around 770 000 outpatient and digital consultations took place.
The Hirslanden Group has once again demonstrated a high level of agility and innovation by establishing and operating repeat testing and eleven Covid-19 vaccination centres throughout Switzerland. Around 9,5 million tests were sent to public and private institutions, companies and schools, and some 1.1 million Covid-19 vaccinations were administered. This made it possible to prevent many Covid-19 cases and lessen the course of the illness for those already infected. Daniel Liedtke, CEO of the Hirslanden Group, says, “Within the context of our handling of the Covid-19 pandemic, we have clearly seen the great importance of prevention. The best medicine is not getting ill in the first place.”
As a result, Hirslanden will be relying on personalised and targeted prevention, such as via genetic evaluations and corresponding prevention programmes for cancer, cardiovascular disease and other illnesses, in the new financial year. Since last year, Hirslanden has boasted a centre of expertise for personalised medicine with its own genetics laboratory in the form of “Hirslanden Precise”. This offers advantages for patients and their relatives, as well as for health-conscious people in general. New gene variants that play a crucial role in preventing familial predispositions towards certain illnesses are continually being discovered. The centre of expertise continuously adapts its services in line with this.
The high weighting of prevention is consistent with Hirslanden’s vision of being a partner of choice when it comes to healthcare. In every life situation: from prevention to aftercare, from birth to old age, at all times – both physically and digitally.
Operational result on target
The turnover of the Hirslanden Group has once again reached pre-pandemic levels and increased over the past financial year compared to the previous year by 6% to CHF 1,885 million (previous year CHF 1,784 million). The EBITDA margin improved from 15.1% to 15.6%.
CEO Daniel Liedtke explains, “This extremely solid result would not have been possible without the dedication of our employees and our partner doctors. I offer my greatest thanks to them for their daily efforts, especially during the stressful and challenging period of the Covid-19 pandemic.”
As a thank you and token of our appreciation for their efforts, the Hirslanden Group will be paying its employees a total of CHF 4 million as a special Covid-19 bonus this year.
Hirslanden is committed to high-quality, responsible and efficiently integrated healthcare that focuses on the needs of the individual. Working together with private and public cooperation partners, the Hirslanden Group prioritises ongoing development of the Continuum of Care concept. From birth to old age, from prevention to healing, Hirslanden is always there, both on a physical and digital level.
Hirslanden differentiates itself from the rest of the market as a service provider with first-class medical and service quality, which is guaranteed by highly qualified independent specialists with years of experience who offer excellent care and services. Interdisciplinary medical centres of expertise, specialised institutes and competent cooperation partners enable optimal, personalised diagnosis and treatment, regardless of case complexity, in both inpatient and outpatient contexts.
The Hirslanden Group operates 17 hospitals in 10 cantons, many of which have an emergency department. It also operates 5 outpatient surgery centres, 18 radiology and 6 radiotherapy institutes. The Group has 2,515 partner doctors and 11,025 employees, 551 of whom are permanently employed doctors. Hirslanden is the largest medical network in Switzerland. In the 2021/22 financial year, the Group generated turnover of CHF 1,885 million. As at 31 March 2022, the Group had treated 109,624 patients for a total of 472,301 inpatient days. The patient mix consists of 51.3% patients with basic insurance, 28.2% with semi-private insurance and 20.5% with private insurance. The Hirslanden Group was formed in 1990 through the merger of several hospitals. Since 2007, it has been part of the international hospital group Mediclinic International plc, which is listed on the London Stock Exchange.